-
Pfizer's palbociclib most commonly used breast cancer drug in clinical trials
pharmafile
December 12, 2018
The drug, which was used in 4% of breast cancer clinical trials conducted in 2018, was investigated for its use as a combination therapy in the vast majority of cases.
-
Eisai and UCL deepen drug discovery alliance
pharmaceutical-technology
December 10, 2018
Japanese pharmaceutical company Eisai has expanded its drug discovery collaboration with University College London (UCL) in the UK for additional five years to 2023......
-
Datwyler starts commercial production at First Line in Pune, India
expressbpd
December 07, 2018
Datwyler has been focusing on high-end rubber formulations for products like lyo and serum vials
-
New potential breast cancer drug identified
expressbpd
December 06, 2018
The new compound is a potential highly effective, next-line treatment
-
Seattle Genetics CEO lifts veil on lightning-quick Adcetris nod
fiercepharma
December 05, 2018
SAN DIEGO—Seattle Genetics CEO Clay Siegall remembers reading about the first FDA approvals under the agency’s new Real Time Oncology Review pilot, secured 24 and 28 days after filing.
-
Pfizer to resume price hiking in 2019; 41 drugs set to increase
November 21, 2018
American pharma firm Pfizer has revealed plans to increase the prices of 41 medicines, the equivalent of 10% of its entire drug portfolio, as of 15 January, 2019.
-
Patient engagement as a new blockbuster drug, not quite yet, study finds
worldpharmanews
November 15, 2018
"Patient engagement has featured prominently in recent healthcare research and policy, probably most notably in the Medicare Access and CHIP Reauthorization Act (MACRA) legislation.
-
Seniors want drug prices in ads. Young people? Eh, whatever: survey
fiercepharma
November 15, 2018
Who wants drug prices in ads? Older people, that’s who. A recent survey by Wells Fargo Securities found that 77% of people 65 and older think pharma companies should be required to disclose prices in ads.
-
AstraZeneca Sells Infant Drug Rights for $1.5B
contractpharma
November 14, 2018
AstraZeneca Sells Infant Drug Rights for $1.5B
-
AstraZeneca gets back to growth, but can it hit $40B by 2023? CEO says yes—again
fiercepharma
November 11, 2018
AstraZeneca CEO Pascal Soriot has repeatedly said his company would finally get back on the upswing in the second half of this year, and he’s put skeptics to rest with strong third-quarter numbers. Now, he’s doubling down on an even more ambitious promise